Solution
AI Strategy & Consulting for Pharmaceutical
Accelerate drug development timelines, optimize clinical trials, and unlock commercial insights with an AI strategy built for pharma's unique demands.
Pharmaceutical companies are investing heavily in AI, but many struggle to move beyond pilots. Adapter helps pharma organizations develop comprehensive AI strategies that deliver value across the drug lifecycle, from discovery through commercialization.
Key Challenges
- FDA Regulatory Uncertainty for AI in Drug Development
- Data Silos Across the Drug Lifecycle
- GxP Validation Requirements
Overview
AI Strategy & Consulting for Pharmaceutical
The pharmaceutical industry is at an inflection point with AI. The potential applications are enormous: AI can accelerate target identification, predict molecular properties, optimize clinical trial design, identify patient populations for precision medicine, streamline regulatory submissions, and improve commercial forecasting. Yet most pharma companies have a collection of disconnected AI experiments rather than a coordinated strategy that maximizes impact across the organization.
Adapter works with pharmaceutical companies to develop AI strategies that span the drug lifecycle. In early discovery, we help organizations evaluate and deploy AI platforms for target identification, lead optimization, and ADMET prediction. In clinical development, we design strategies for AI-driven trial site selection, patient recruitment optimization, endpoint prediction, and real-world evidence generation. In commercial operations, we plan AI initiatives for launch sequencing, HCP targeting, patient journey analytics, and market access optimization. For each initiative, we assess data availability, model feasibility, regulatory considerations, and expected impact on timelines and costs.
Our strategies address the unique regulatory and organizational challenges of pharmaceutical AI. This includes FDA guidance on AI in drug development, 21 CFR Part 11 compliance for electronic records, validation requirements for GxP-adjacent AI systems, and the cross-functional governance needed when AI spans R&D, clinical, regulatory, and commercial functions. We also help pharmaceutical organizations build the internal capabilities needed to sustain AI innovation, including data infrastructure modernization, MLOps platforms, talent development, and partnerships with AI-focused biotechs and academic institutions. The goal is a strategy that accelerates your pipeline, reduces development costs, and positions your organization to compete in an industry where AI capability is rapidly becoming a competitive necessity.
What we deliver
Solutions
- 01
Lifecycle-Spanning AI Roadmap
- 02
Pharma Data Infrastructure Strategy
- 03
GxP-Aware AI Governance
- 04
Cross-Functional AI Governance Model
Industry Challenges
Problems we solve
FDA Regulatory Uncertainty for AI in Drug Development
FDA guidance on AI in drug discovery and clinical development is evolving, creating uncertainty about how AI-generated evidence will be reviewed and accepted.
Data Silos Across the Drug Lifecycle
Discovery data, clinical trial data, real-world evidence, and commercial data typically reside in separate systems with different formats, governance, and access controls.
GxP Validation Requirements
AI systems that influence GxP-regulated processes must meet validation standards outlined in 21 CFR Part 11 and ICH guidelines, adding complexity to model deployment.
Cross-Functional Organizational Alignment
AI initiatives in pharma often span R&D, clinical, regulatory, medical affairs, and commercial teams, requiring governance structures that cross traditional organizational boundaries.
What We Build
Our approach
Lifecycle-Spanning AI Roadmap
We develop strategies that identify and prioritize AI opportunities across discovery, development, regulatory, manufacturing, and commercial operations, ensuring coherent investment across the pipeline.
Pharma Data Infrastructure Strategy
Our strategies include plans for unifying data across the drug lifecycle, including FAIR data principles, ontology alignment, and governance frameworks that enable cross-functional AI initiatives.
GxP-Aware AI Governance
We design validation and governance frameworks for AI systems that operate in or adjacent to GxP environments, aligning with 21 CFR Part 11, ICH guidelines, and emerging FDA AI guidance.
Cross-Functional AI Governance Model
We establish governance structures, review boards, and decision frameworks that enable AI initiatives to operate across traditional pharma organizational boundaries.
Results
What you can expect
30% reduction in lead optimization cycle time
AI-driven molecular property prediction and optimization reduce the time from hit identification to preclinical candidate selection.
25% improvement in clinical trial enrollment speed
AI-optimized site selection and patient identification accelerate enrollment timelines for critical clinical studies.
Unified AI governance across 4 functional areas
Cross-functional governance frameworks enable coordinated AI investment and reduce duplicative efforts across R&D, clinical, regulatory, and commercial teams.
FAQ
Common questions
Things clients typically ask about ai strategy in this industry.
Ready to get started?
Tell us about your project and we will scope an engagement that fits.